GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang P.

Both Indiana University and Memorial Sloan Kettering Cancer Center (MSKCC) have published their series’ of salvage high-dose ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...

Dr. Heidenreich notes that among the 86% of seminoma CSI patients, 15-30% relapse, of which 95% relapse in the retroperitoneum, nearly all relapses have good prognosis, and these patients are now CS ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Joseph Allen discussing PSA response and survival based on metastatic site in patients with ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...